Skip to main content
OpenTrials

Clinical trial condition

Skin Neoplasms

Explore clinical trials studying Skin Neoplasms. Study availability and eligibility vary by location and protocol.

2,109 public trials 360 recruiting studies
Refine in advanced search Browse all conditions

Skin Neoplasms trial results

Active, Not Recruiting

A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients

NCT06540391

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
Locations
  • Centre Georges Francois Leclerc Dijon, France
  • CHU de Lille - Hopital Claude Huriez Lille, France
  • Centre Leon Berard Lyon, France
  • AP-HM - Hopital de la Timone Marseille, France
View all 19 locations
View Trial Details
Active, Not Recruiting

A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

NCT04606472

Conditions
Adenocarcinoma, Breast Diseases, Breast Neoplasms, +43 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Chongqing University Cancer Hospital Chongqing, Chongqing Municipality, China
  • The First Affiliated Hospital of Xiamen University Xiamen, Fujian, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
View Trial Details
Active, Not Recruiting

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

NCT04674683

Conditions
Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, +17 more
Locations
  • Comprehensive Blood and Cancer Center Bakersfield, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Innovative Clinical Research Institute (ICRI) Pasadena, California, United States
  • Emad Ibrahim, MD, INC Redlands, California, United States
View all 139 locations
View Trial Details
Active, Not Recruiting

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
Locations
  • Highlands Oncology Group ( Site 1943) Springdale, Arkansas, United States
  • UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1918) Los Angeles, California, United States
  • UCSF Medical Center at Mission Bay ( Site 1929) San Francisco, California, United States
  • Yale-New Haven Hospital-Yale Cancer Center ( Site 1933) New Haven, Connecticut, United States
View all 165 locations
View Trial Details
Active, Not Recruiting

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

NCT05309421

Conditions
Melanoma, Melanoma Stage IV, Neoplasms, +11 more
Locations
  • Melanoma Institute Australia Wollstonecraft, New South Wales, Australia
  • One Clinical Research Nedlands, Western Australia, Australia
  • Divisione di Oncologia Medica del Melanoma Milan, Italy
  • Instituto Nazionale Tumori IRCCS Fondazione Naples, Italy
View Trial Details
Active, Not Recruiting

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

NCT05653882

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +36 more
Locations
  • City of Hope Duarte, California, United States
  • UCLA Los Angeles, California, United States
  • UCSD San Diego, California, United States
  • UCSF San Francisco, California, United States
View all 20 locations
View Trial Details
Active, Not Recruiting

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

NCT03470922

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +9 more
Locations
  • Local Institution - 0010 Tucson, Arizona, United States
  • Local Institution - 0020 Los Angeles, California, United States
  • Coastal Integrative Cancer Care San Luis Obispo, California, United States
  • Local Institution - 0116 Santa Barbara, California, United States
View all 127 locations
View Trial Details
Active, Not Recruiting

Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients

NCT06551064

Conditions
Melanoma, Melanoma Stage III, Melanoma, Stage II, +11 more
Locations
  • Formycon Investigative Site Sarajevo, Bosnia and Herzegovina
  • Formycon Investigative Site Sofia, Bulgaria
  • Formycon Investigative Site Tartu, Estonia
  • Formycon Investigative Site Batumi, Georgia
View all 17 locations
View Trial Details

Related conditions